5-[2-(2-methyl-2H-pyrazol-3-ylamino)pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile | 1356225-72-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-[2-(2-methyl-2H-pyrazol-3-ylamino)pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile
• 英文别名: US8962609, Dmx-27；5-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile
• CAS: 1356225-72-3
• 化学式: C₁₉H₁₉N₇
• 分子量: 345.407
• InChiKey: DAZUIYGZOWVNPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  82.7
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] PYRIMIDINES AU TITRE D'INHIBITEURS DE PROTÉINES KINASES IKK EPSILON ET/OU TBK-1, LEURS PROCÉDÉS DE SYNTHÈSE ET LES COMPOSITIONS PHARMACEUTIQUES LES INCLUANT
  申请人：DOMAINEX LTD

  公开号：WO2012010826A1

  公开（公告）日：2012-01-26

  C Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases ΙΚΚε and/or TBK-1 : in which: R1 represents an aliphatic heterocyclyl group having 4, 5, 6 or 7 ring atoms, bonded to the phenyl group shown in formula I through a ring nitrogen atom, and optionally substituted by one or more substituents defined in the Specification; R2 represents a phenyl or heteroaryl group which is optionally substituted by one or more substituents defined in the Specification; and each of R3 and R4 independently represents a hydrogen atom or a C1-4 alkyl group.

  通用式（I）的化合物和其盐在治疗与蛋白激酶IKKε和/或TBK-1的异常活性相关的疾病中是有用的：其中：R1代表具有4、5、6或7个环原子的脂肪杂环基团，通过一个环氮原子与式I中所示的苯基结合，并且可以选择性地由规范中定义的一个或多个取代基取代；R2代表一个苯基或杂环基团，可以选择性地由规范中定义的一个或多个取代基取代；每个R3和R4独立地表示一个氢原子或一个C1-4烷基基团。
• PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Perrior Trevor Robert

  公开号：US20130267491A1

  公开（公告）日：2013-10-10

  C Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKKε and/or TBK-1: in which: R 1 represents an aliphatic heterocyclyl group having 4, 5, 6 or 7 ring atoms, bonded to the phenyl group shown in formula I through a ring nitrogen atom, and optionally substituted by one or more substituents defined in the Specification; R 2 represents a phenyl or heteroaryl group which is optionally substituted by one or more substituents defined in the Specification; and each of R 3 and R 4 independently represents a hydrogen atom or a C 1-4 alkyl group.

  通式（I）的化合物及其盐在治疗与蛋白激酶IKKε和/或TBK-1的异常活性相关的疾病方面是有用的：其中：R1代表通过一个环氮原子与通式I中所示的苯基相连的具有4、5、6或7个环原子的脂肪族杂环基，可选地被本说明书中定义的一个或多个取代基取代；R2代表一个苯基或杂环基，可选地被本说明书中定义的一个或多个取代基取代；R3和R4各自独立地代表氢原子或C1-4烷基。
• PROCESS FOR PRODUCTION OF FINELY FIBROUS CELLULOSE COMPOSITE PREPREG SHEET, PROCESS FOR PRODUCTION OF FINELY FIBROUS CELLULOSE COMPOSITE SHEET, AND PROCESS FOR PRODUCTION OF FINELY FIBROUS CELLULOSE COMPOSITE LAMINATE SHEET
  申请人：Oji Holdings Corporation

  公开号：EP2660276A1

  公开（公告）日：2013-11-06

  The present invention relates to a method of producing a finely fibrous cellulose composite prepreg sheet, the method including a preparation step of mixing an emulsion of a reactive compound with an aqueous suspension containing a finely fibrous cellulose to prepare a mixed liquid, a papermaking step of dewatering the mixed liquid by filtration on a porous substrate to form a water-containing sheet, and a drying step of heating and drying the water-containing sheet; and a method of producing a finely fibrous cellulose composite sheet, the method including subjecting the finely fibrous cellulose composite prepreg sheet produced by the aforementioned production method to a curing treatment. The present invention is able to provide a method of producing a finely fibrous cellulose composite prepreg sheet with good efficiency, a method of producing a finely fibrous cellulose composite sheet, and a method of producing a finely fibrous cellulose composite laminate sheet.

  本发明涉及一种生产细纤维素复合预浸料片材的方法，该方法包括将活性化合物乳液与含有细纤维素的水悬浮液混合以制备混合液体的制备步骤，在多孔基底上通过过滤将混合液体脱水以形成含水片材的造纸步骤，以及加热和干燥含水片材的干燥步骤；以及一种生产细纤维素复合片材的方法，该方法包括将通过上述生产方法生产的细纤维素复合预浸片材进行固化处理。本发明能够提供一种生产效率高的细纤维素复合预浸料板材的方法、一种生产细纤维素复合板材的方法和一种生产细纤维素复合层压板材的方法。
• Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them
  申请人：Domainex Limited

  公开号：EP2595964B1

  公开（公告）日：2015-04-29
• USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER
  申请人：Del Mar Pharmaceuticals

  公开号：EP3125920A2

  公开（公告）日：2017-02-08